Bioequivalence Study of Ramipril 10 mg Capsules Under Fed Conditions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was conducted as an open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioavailability study comparing ramipril 10 mg capsules of Ohm Laboratories Inc., with Altace® capsule 10 mg (containing ramipril 10 mg) manufactured by King Pharmaceuticals Inc, Bristol and Distributed by Monarch Pharmaceuticals Inc, Bristol in healthy, adult, male, human subjects under fed condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioequivalence Study of Ramipril 10 mg Capsules Under Fasting Conditions

NCT00879476

Healthy

COMPLETED NA

Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions

NCT01164761

Healthy

COMPLETED PHASE1

Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions

NCT01164774

Healthy

COMPLETED PHASE1

Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions

NCT00829530

Healthy

COMPLETED PHASE1

Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions

NCT00828321

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single oral dose of ramipril 10 mg capsule was administered with 240 mL of drinking water at ambient temperature 30 minutes after start of a high-fat high-caloric breakfast under the supervision of trained study personnel.

A total of thirty-two (32) subjects were randomized to receive a single oral dose of the test (T) and reference (R) formulation of ramipril 10 mg capsule. One subject (subject No. 18) was withdrawn and one dropped out (subject No. 10) from the study in period I. One subject (subject No. 20) dropped out and two subjects were withdrawn (subject No. 27, 29) from the study in period II.

A total of twenty-seven (27) subjects completed both the periods of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA

Group Type EXPERIMENTAL

Ramipril 10mg capsules

Intervention Type DRUG

2

ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA

Group Type ACTIVE_COMPARATOR

Ramipril 10mg capsules

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramipril 10mg capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Were in the age range of 18-45 years.
2. Were neither overweight nor underweight for the corresponding height as per the Life Insurance Corporation of India height/weight chart for non-medical cases.
3. Had voluntarily given written informed consent to participate in this study.
4. Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study.
5. Had a non-vegetarian diet habit.

Exclusion Criteria

1. Hypersensitivity, allergy to ramipril or related group of drugs.
2. History of anaphylaxis/anaphylactoid reactions.
3. History of fever in the week preceding the study.
4. History of seizures and sleep disorders.
5. History of chronic cough, bronchial asthma.
6. Subject who had sitting systolic blood pressure of less than 90 mmHg or \>140 mmHg and diastolic blood pressure of less than 60 mmHg or \> 90 mmHg at predose.
7. History of frequent syncopal attacks, frequent palpitations.
8. History of angina, myocardial infarction or angioedema.
9. History of severe diarrhea or vomiting in the week preceding the study.
10. History of dry cough.
11. History of congestive heart failure.
12. Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
13. Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis infection.
14. Presence of values which were significantly different from normal reference ranges and/or judged clinically significant for hemoglobin, total white blood cells count, differential WBC count or platelet count.
15. Positive for urinary screen testing of drugs of abuse (opiates or cannabinoids).
16. Presence of values which were significantly different from normal reference ranges and/or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol.
17. Clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (\>4/HPF), glucose (positive) or protein (positive).
18. Clinically abnormal ECG or Chest X-ray.
19. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or hematological disease, diabetes or glaucoma.
20. History of any psychiatric illness, which might impair the ability to provide written informed consent.
21. Regular smokers who smoked more than 10 cigarettes daily or had difficulty abstaining from smoking for the duration of each study period.
22. History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or had difficulty in abstaining for the duration of each study period.
23. Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.
24. Participation in any clinical trial within 12 weeks preceding Day 1 of this study.
25. Subjects who, through completion of this study, had donated and/or lost more than 350 mL of blood in the past 3 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes